Bristol-Myers Squibb has signed a definitive agreement to acquire US-based Amira Pharmaceuticals for a price of $325m, with additional payments totalling $150m.
Under the agreement, Bristol-Myers Squibb will acquire all of Amira’s issued and outstanding shares of capital stock and stock equivalents.
Bristol-Myers Squibb will also secure Amira’s fibrosis programme, including lead asset AM152, and the pre-clinical autotaxin programme.
Bristol-Myers Squibb Research and Development executive vice president, chief scientific officer and president Elliott Sigal said the acquisition represents a targeted set of transactions designed to enrich the company’s pipeline with potential medicines to help patients in need.
The closing of the transaction is subject to customary regulatory approvals.